Generic Name and Formulations:
Gadodiamide 287mg/mL; soln for IV inj; preservative-free.
Indications for OMNISCAN:
For use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues. For use in MRI to facilitate the visualization of lesions with abnormal vascularity within the thoracic (noncardiac), abdominal, pelvic cavities, and the retroperitoneal space.
Adults and Children:
<2yrs: not established. Give as a bolus IV inj, followed by 5mL normal saline flush to ensure complete injection. ≥2yrs: CNS: 0.2mL/kg (0.1mmol/kg). Kidney: 0.1mL/kg (0.05mmol/kg). Intrathoracic (noncardiac), intra-abdominal, pelvic cavities: 0.2mL/kg (0.1mmol/kg).
Chronic, severe kidney disease (GFR <30mL/min/1.73m2). Acute kidney injury.
Not for intrathecal use. Nephrogenic systemic fibrosis (NSF).
Not for intrathecal use; may cause convulsions, coma, sensory and motor neurologic deficits. Increased risk of nephrogenic systemic fibrosis in chronic kidney disease or acute kidney injury (see Contraindications). Screen for renal dysfunction. Do not exceed recommended dose and allow sufficient time for drug elimination before re-administration. Have emergency resuscitative equipment available. History of asthma or other allergic disorders. Monitor for signs/symptoms of hypersensitivity reactions during and up to several hrs after administration. Increased risk of gadolinium retention with multiple lifetime doses, in pregnant patients, children, and those with inflammatory conditions; minimize repetitive imaging studies. Renal impairment: use lowest effective dose. Avoid extravasation. Interpreting Omniscan MRI scans without a companion non-contrast MRI. Elderly. Pregnancy. Nursing mothers.
Gadolinium-based contrast agent.
Interferes with serum calcium measurements with some colorimetric methods.
Nausea, headache, dizziness; cardiac failure, arrhythmia, MI, hypersensitivity reactions.
Vials (5mL, 10mL, 15mL, 20mL)—10; Prefilled syringes (10mL, 15mL, 20mL)—10; Prefill Plus needle-free system (15mL, 20mL)—10 (prefilled syringe + sodium chloride 0.9% inj flush syringe)
Clinical Pain Advisor Articles
- Opioid Use Disorders: Advances in Pharmacotherapy Provide Long-term Results
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- FDA Taps Social Media to Identify and Assess Emerging Drug Abuse Threats
- Buffered Lidocaine May Be Superior to Nonbuffered Lidocaine for Inferior Alveolar Nerve Block
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Marijuana's Uncertain Status: Closing the Gap Between State and Federal Policies